Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Ertugliflozin/Metformin vs Segluromet
NCT07266779Phase 1Completed
- Sponsor
- Humanis
- Start
- Aug 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ertugliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Peak Plasma Concentration at 72 hours and Area Under the Curve from time zero to time of last measurable concentration at 72 hours. Started Aug 2025; status: completed.
02
Drugs
ertugliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07266779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07266779.